uu.seUppsala University Publications
Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
Proteochemometric Modeling of Drug Resistance over the Mutational Space for Multiple HIV Protease Variants and Multiple Protease Inhibitors
Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Pharmacy, Department of Pharmaceutical Biosciences. (Proteochemometric group)
Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Pharmacy, Department of Pharmaceutical Biosciences. (Proteochemometric group)
2009 (English)In: Journal of chemical information and modeling, ISSN 1549-9596, Vol. 49, no 5, 1202-1210 p.Article in journal (Refereed) Published
Abstract [en]

The main therapeutic targets in HIV are its protease and reverse transcriptase. A major problem in treatment of HIV is the ability of the virus to develop drug resistance by accumulating mutations in its targets. Acquiring detailed understanding of the molecular mechanisms for the interactions of drugs with mutated variants of the HIV virus is mandatory to be able to design inhibitors that can evade the resistance. Here we have used proteochemometric modeling to simultaneously analyze the interactions of 21 protease inhibitors with 72 unique protease variants. Inhibition data (pK(i)) were correlated to descriptions of chemical and structural properties of the inhibitors and proteases. The proteochemometric model obtained showed excellent fit and predictive ability (R(2)=0.92, Q(2)=0.83, Q(2)(inh)=0.78) and provided quantitative assessments for the contribution of each mutation and their combinations to the decrease in inhibitor activity, both for the whole compounds series as well as for individual compounds. The model revealed the most deleterious mutations in the protease to be D30N, V32I, G48V, I50V, I54V, V82A, I84V, and L90M. The model was further used to identify molecular properties of chemical compounds that are important for their inhibition of multimutated protease variants. Our results give directions how to design novel improved inhibitors.

Place, publisher, year, edition, pages
2009. Vol. 49, no 5, 1202-1210 p.
National Category
Pharmaceutical Sciences
Identifiers
URN: urn:nbn:se:uu:diva-104203DOI: 10.1021/ci800453kISI: 000266327000007PubMedID: 19391634OAI: oai:DiVA.org:uu-104203DiVA: diva2:219536
Available from: 2009-05-27 Created: 2009-05-27 Last updated: 2013-12-12Bibliographically approved

Open Access in DiVA

No full text

Other links

Publisher's full textPubMed

Authority records BETA

Lapins, MarisWikberg, Jarl E. S

Search in DiVA

By author/editor
Lapins, MarisWikberg, Jarl E. S
By organisation
Department of Pharmaceutical Biosciences
Pharmaceutical Sciences

Search outside of DiVA

GoogleGoogle Scholar

doi
pubmed
urn-nbn

Altmetric score

doi
pubmed
urn-nbn
Total: 537 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf